chevron_leftBack
As of 13 June 2026, NeoImmuneTech, Inc. has a market cap of $30.68M USD, ranking #34094 globally and #4778 in the United States.
It ranks #3074 in the Healthcare sector, and #589 in the Biotechnology industry.
Key Stats
Market Cap
$30.68MUSD
46.67B KRW
Enterprise Value
-$2.4MUSD
-3.66B KRW
Revenue (TTM)
$62.35KUSD
94.82M KRW
EBITDA (TTM)
-$14.97MUSD
-22.84B KRW
Net Income (TTM)
-$20.91MUSD
-31.8B KRW
PS Ratio
492.1
PB Ratio
0.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Luke Yun Oh
open_in_new
Employees
52
Founded
2014
Website
neoimmunetech.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.9% | -7.6% | -13% | -37% | -23% | -59% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
950220
네오이뮨텍은 Korean Depository Receipts
ISIN: KR8840140006
Shares Out.:
Shares Outstanding:
33.528M1
Shares Float:
27.745M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
468 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About NeoImmuneTech, Inc.
NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea. It is developing NT-I7, an IL-7 class T- cell amplifier to treat acute radiation syndrome; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
594K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
521K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
90K%
|
-
|
|
NYSE: IQV
|
$26.3B
86K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
81K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
59K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
156K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
146K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
138K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
138K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
92K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
84K%
|
-
|
chevron_leftBack